Precigen Reports $21.6M Q1 PAPZIMEOS Revenue and $0.02 EPS Loss
Precigen generated $21.6 million of Q1 net product revenue from PAPZIMEOS, enrolled 400 patients (25% in community settings), and reported a $0.02 per-share loss versus a $0.03 consensus loss. Cash and equivalents totaled $56.7 million as of March 31, 2026, and management forecasts cash-flow break-even by year-end.
1. Q1 Financial Results
Precigen recorded $21.6 million of net product revenue from PAPZIMEOS in the first quarter of 2026 and delivered a $0.02 per-share loss, outperforming the $0.03 consensus loss estimate. The company closed the quarter with $56.7 million in cash, cash equivalents and investments.
2. PAPZIMEOS Commercial Progress
Enrollment in the PAPZIMEOS patient hub reached 400 registered patients, 25% of whom are treated in community settings, reflecting broad integration beyond major medical centers. Coverage now spans approximately 297 million US insured lives, and a permanent J-code implemented April 1 is expected to streamline reimbursements and accelerate site activations.
3. Outlook and Pipeline Development
Management anticipates reaching cash-flow break-even by the end of 2026, bolstered by ongoing PAPZIMEOS revenues. Updated durability of response data will be presented at the ASCO Annual Meeting, and an AdenoVerse pipeline update is planned by year-end alongside the third annual RRP Awareness Day on June 11.